

## PRESS RELEASE

### **Temedica Appoints Dr Christina Wagner as Chief Financial Officer**

**Munich, Germany, 28. October 2021** – Temedica GmbH, a Munich-based digital health company, announced today that from 1st of October 2021, Dr Christina Wagner was appointed Chief Financial Officer (CFO). Ms. Wagner joined Temedica after driving financial and strategy performance as CFO and Managing Director of coliquio GmbH, an online expert network for physicians.

Dr Wagner brings more than 20 years of experience in financial positions in various companies including OmniaMed Holding group where she took responsibility for two financial departments in the German and UK subsidiaries. For almost 10 years, she worked as a consultant and interim manager at Ventac Partner Consulting taking care of various strategic and operative consulting projects. Dr Wagner is a founding partner of Inveni Capital, a German-Finnish Biotech venture capital firm. At MWG Biotech AG (today Eurofins Genomic GmbH) she was responsible for reorganization, budget planning, strategy, and preparations for exit. Christina Wagner started her career as a consultant at The Boston Consulting Group and holds a PhD in chemical engineering from the University of Dortmund.

Gloria Seibert, CEO of Temedica:

“I am delighted to welcome Christina Wagner to Temedica. With more than 20 years of experience, Christina truly is a financial expert for the healthcare industry. Throughout her career, Christina has demonstrated tremendous talent in driving financial performance and serving as a strategic sparring partner. Her experience will be of great benefit for Temedica to grow and achieve our vision to develop innovative, digital solutions that focus on the patients.”

Christina Wagner, CFO at Temedica:

“Temedica is an inspiring and forward-looking company, which brings digital therapy-supporting guidance to patients. I am excited to join Temedica and look forward very much to working on inspiring projects, which are based on a cutting-edge technology allowing for novel insights from real-world evidence and provide a very interesting business model for partnerships with the biopharma industry. Together we can accomplish a lot for the future, and I am confident that with Temedica’s patient-centric solution, we will change the healthcare sector.”

## **About Temedica GmbH**

Temedica develops state-of-the-art digital patient companions for an ever-growing number of conditions. The apps help patients with personalized guidance, support faster and more accurate diagnosis, and navigate patients through the healthcare system considering their individual needs. They encourage users to actively take their health into their own hands. Through direct and long-term interaction with patients, Temedica generates unique and previously unknown insights and real-world evidence about disease progression and the individual effectiveness of therapies. Temedica is supported by a consortium of renowned investors with longstanding track-records in the biopharmaceutical industry, including the MIG funds, the family office of the Struengmann family, Santo, and Salvia. Further information is available at <https://temedica.com/en/>.

## **International Media and IR Contact**

MC Services AG

Dr. Brigitte Keller, Katja Arnold

T +49 89 210228 0

UK: Shaun Brown

M: +44 7867 515 918

Email: [temedica@mc-services.eu](mailto:temedica@mc-services.eu)